What Is This Papule on the Sole?

VOLUME: 14 PUBLICATION DATE: May 15 2006
Sidebars_in_article: 

On The Horizon

Article Reference: 

Recently, reports have been made with alternate techniques used to reaffirm biopsy findings. For example, confocal microscopy (CM) has been shown effective in correlation with H&E staining.21 In this report, a correlation was noted between histologic specimens and in vivo CM imaging of an EP. CM allowed in vivo observation of tumor nests and tumor cell properties such as uniform cells and prominent vasculature.
CM, an optical imaging tool, allows for high resolution, non-invasive imaging
in vivo. CM visualizes clear thin sample sections, blocking background haze, so that cellular and nuclear detail can be evaluated quickly and repeatedly. This decreases wait time and allows for more convenient monitoring of disease progression. Use of CM has shown promise in non-EP studies and may soon be extrapolated to EP and other skin lesions.22
Also on the forefront, is the possible use of flow cytometry to assess malignant potential. A range of malignant tumors have been found, via flow cytometry, to have DNA aneuploidy with similar studies attempting to extrapolate this concept in application to EPs. This is a very recent and interesting attempt to asses the malignancy of skin lesions such as EP.23

Issue Number: 
5_2006
author: 
By Rashid M. Rashid, B.S., and Amor Khachemoune, M.D., C.W.S.

Patient Presentation A 46-year-old male presented with a small growth, which he had for at least 10 years on the left sole. The lesion was asymptomatic, but it was accidentally slightly traumatized a few days prior to his presentation. The patient’s past medical, surgical and family histories were non-contributory. On examination of the left sole, there was a 5-mm x 5-mm slightly erythematous firm papule with a smooth central area and a distinguished collarette of skin on the periphery localized to the left sole toward the lateral aspect of the heel. On palpation the papule seems to be firm and well circumscribed, and no fluid or other content could be extruded on pressure. The rest of the examination was within normal limits. Diagnosis: Eccrine Poroma The term “poroma” refers to benign neoplasms with “poroid” or terminal ductal differentiation. The first eccrine poroma (EP) was described 50 years ago by Goldman, Pinkus and Rogin as a tumor of sweat gland origin.1 Seven years later, Pinkus and Mehregan described a malignant variant termed porocarcinoma.2 This detailed description included a comparison and differentiation from Paget’s disease based on characteristics such as the lack of tonofibrils and the presence of glycogen noted in EPs. Although EPs are considered benign, reports have suggested porocarcinomas exist as a progression of EPs.3 The first porocarcinoma presentation included lymphedema of the lower extremities with multiple widespread metastatic nodules, thus emphasizing the importance of recognizing and diagnosing such seemingly benign lesions.2Etiology and Prevalence The pathogenesis of EPs remains unknown. However, reports have noted associations with scars,4 radiation5 and trauma.6EPs typically present after 40 years of age, with only eight cases reported in patients 18 years or younger.7 The prevalence of EPs has not been reported. No relation has been noted with race, and no inheritance pattern has been described.Clinical FeaturesPhysical appearance of EP and descriptions vary. Typical appearance may consist of a 2-mm to 12-mm soft sessile nodule protruding from a circular depression. However, an EP can be an erythematous, pink or cyanotic papule or nodule. EPs can also be rubbery, or a verrucus-like plaque, or even an ulcerative nodule. These lesions are often moist, exophytic and can reach 3 cm in diameter with a smooth or crusted surface. A keratotic collar may also be noted, as well as a moat-like depression. Other variants reported include pigmented EPs, in which pigmentation is associated with melanocyte enhancing endothelin-1 expression.8The majority of EPs occur on the soles of the lower extremities, but can also be found on palms, trunk, upper extremities, and head and neck region.3 When EP lesions appear in clusters, this is referred to as “poromatosis.”9 EPs tend to be asymptomatic but bleed with trauma, and thus make this the common clinical presentation. Itching or pain should raise the suspicion of malignancy.10DiagnosisDiagnosis is confirmed primarily with histological analysis. On noting a lesion with features of EPs, the differential diagnosis should include squamous cell carcinoma (SCC), basal cell carcinoma (BCC), malignant melanoma, amelanotic melanoma, botryomycoma, fibrokeratoma and pyogenic granuloma. A thorough workup should be preformed and must include a biopsy. Even lesions with minimal physical abnormalities have been reported as malignant.11 Interestingly, although a lesion clinically appearing as an EP may be a porocarcinoma, the opposite is also true in which a lesion clinically mimicking a porocarcinoma type lesion may be EP,12 emphasizing the importance of complete excisional biopsy and careful analysis. Pathogenesis and Histology On biopsy, EP is noted as a solid tumor. A clear circumscribed margin exists between adjacent normal epidermal keratinocyte and the EP population of smaller cuboidal cells with darker monomorphous nuclei and scant cytoplasm. The deeply basophilic oval nuclei give these cells an overall basaloid nature. However, unlike BCC, these cells do have glycogen, do not palisade, and do not express transcriptional factor Gli1.13 EPs may have a highly vascular polymorphous pattern and have been known to mimic amelanotic melanoma.14 This highly vascular stroma can also mimic pyogenic granuloma, and is differentiated by the high glycogen content. EP cells may have cystic spaces devoid of any lining. These cystic spaces, pseudohorn cysts, can make differentiation from seborrheic keratosis difficult.On closer examination, cells are noted to be united by intracellular bridges that are less distinct than those in SCC. Rarely are mitotic figures seen, and despite the low cell proliferation, nests of necrosis may be seen. Individual tumor nests can be separated by normal epidermis thus mimicking hydroacanthoma simplex.EP staining shows strongly PAS positive cells due to the high glycogen content. Ductal differentiation can be confirmed by CEA staining. Eccrine enzymes also predominate. Phytohemagglutinine (PHA) can be used to differentiate EPs from porocarcinoma as PHA doesn’t stain the former. From a genetic perspective, and also supporting the theory of progression to carcinogenesis, both EPs and porocarcinomas express p53;15 however, the stabilization of the produced p53 seems to be the differentiating factor.16Immunohistochemical studies have attempted to elucidate the histogenesis of poroid neoplasms. However, debate still exists. For example, based on histochemistry and electron microscopy studies, EP was thought to be derived from the basal cells (outer cells) of the intraepidermal portion of the eccrine duct, also known as the acrosyringium.17 However, other immunochemical studies speculate that EPs originate via the proliferation and expansion of ductal and/or epidermal basal cells.18, 19 Overall, a trend has arisen to separate poromas based on origin as apocrine or eccrine poromas.20 Currently, various names exist for EPs depending on histology. Intraepidermal poromas, also known as hidroacanthoma simplex, are nests of cells with tubular differentiation confined to the epidermis. Juxtaepidermal poromas are noted as nests of thick cords of cells in continuity with the epidermis and involving the superficial dermis. Dermal poromas, also known as dermal duct tumors, are confined to the dermis. ManagementTreatment of choice is surgical excision. Recently, alternate treatments have been attempted including case reports on use of imiquimod cream (Aldara).24 As EP is considered benign, prognosis is good without complications. No known prevention exists.Our patient underwent excision of the lesion followed by layered closure. No complications were noted. At 6-month follow-up, no reoccurrence was noted. Disclosure: The authors have no conflict of interest with any subject matter discussed in this month’s column.    

Editor(s): 
Amor Khachemoune, M.D., C.W.S.
References: 

References:1. Goldman P, Pinkus H, Rogin JR. Eccrine poroma; tumors exhibiting features of the epidermal sweat duct unit. AMA Arch Derm. 1956 Nov;74(5):511-21.2. Pinkus H, Mehregan AH. Epidermotropic Eccrine Carcinoma. a Case Combining Features of Eccrine Poroma and Paget’s Dermatosis. Arch Dermatol. 1963 Nov;88:597-606.3 Robson A, Greene J, Ansari N, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol. 2001 Jun;25(6):710-20.4. Nemoto I, Akiyama N, Aoyagi S, et al. Eccrine porocarcinoma and eccrine poroma arising in a scar. Br J Dermatol 2004 Jun;150(6):1232-3.5. Penneys NS, Ackerman AB, Indgin SN, et al. Eccrine poroma: two unusual variants. Br J Dermatol. 1970 Jun;82(6):613-5.6. Johnson RC, Rosenmeier GJ, Keeling JH, 3rd. A painful step. Eccrine poroma. Arch Dermatol. 1992 Nov;128(11):1530-3.7. Orlandi C, Arcangeli F, Patrizi A, et al. Eccrine poroma in a child. Pediatr Dermatol. 2005 May;22(3):279-80.8. Lan CC, Yu HS, Wu CS, et al. Pigmented eccrine poroma with enhanced endothelin-1 expression: implications for mechanism of hyperpigmentation. Br J Dermatol. 2005 May;152(5):1070-2.9. Goldner R. Eccrine poromatosis. Arch Dermatol 1970 May;101(5):606-8.10. Al-Ahwal MS, Sawan AS, Zimmo SK. Malignant eccrine poroma. Saudi Med J. 2005 May;26(5):859-61.11. Sheff JS, Macdougall DB. Unusual case of porocarcinoma of the foot with no clinically evident dermatologic manifestations. J Foot Ankle Surg. 2005 Sep;44(5):412-4.12. Jagdeo J, Robinson-Bostom L, Long T. Unusual clinical presentation of benign eccrine poroma. J Am Acad Dermatol. 2006 Apr;54(4):733-4.13. Hatta N, Hirano T, Kimura T, et al. Molecular diagnosis of basal cell carcinoma and other basaloid cell neoplasms of the skin by the quantification of Gli1 transcript levels. J Cutan Pathol. 2005 Feb;32(2):131-6.14. Altamura D, Piccolo D, Lozzi GP, et al. Eccrine poroma in an unusual site: a clinical and dermoscopic simulator of amelanotic melanoma. J Am Acad Dermatol. 2005 Sep;53(3):539-41.15. Akalin T, Sen S, Yuceturk A, et al. P53 protein expression in eccrine poroma and porocarcinoma. Am J Dermatopathol. 2001 Oct;23(5):402-6.16. Takata M, Hashimoto K, Mehregan P, et al. Genetic changes in sweat gland carcinomas. J Cutan Pathol. 2000 Jan;27(1):30-5.17. Hashimoto K, Lever WF. Eccrine Poroma; Histochemical and Electron Microscopic Studies. J Invest Dermatol. 1964 Oct;43(237-47.18. Moll I, Moll R. Comparative cytokeratin analysis of sweat gland ducts and eccrine poromas. Arch Dermatol Res. 1991 Jul;283(5):300-9.19. Watanabe S, Mogi S, Ichikawa E, et al. Immunohistochemical analysis of keratin distribution in eccrine poroma. Am J Pathol. 1993 Jan;142(1):231-9.20. Futagami A, Aoki M, Niimi Y, et al. Apocrine poroma with follicular differentiation: a case report and immunohistochemical study. Br J Dermatol. 2002 Oct;147(4):825-7.21. Tachihara R, Choi C, Langley RG, et al. In vivo confocal imaging of pigmented eccrine poroma. Dermatology. 2002 204(3):185-9.22. Gerger A, Horn M, Koller S, et al. Confocal examination of untreated fresh specimens from basal cell carcinoma: implications for microscopically guided surgery. Arch Dermatol. 2005 Oct;141(10):1269-74.23. Burra UK, Singh A, Saxena S. Eccrine porocarcinoma (malignant eccrine poroma): a case report. Dermatol Online J. 2005 Aug;11(2):17.24. Jo JH, Chin HW, Kim MB, et al. A case of eccrine poroma treated with 5% imiquimod cream. J Dermatol. 2005 Aug;32(8):691-3.

0
No votes yet

REVIEW OUR OTHER
HEALTHCARE BRANDS

Check out our other resources for healthcare professionals of all specialties.

  • WOUNDS
  • Todays Wound Clinic
  • Podiatry Today
  • Ostomy Wound Management